Population Pharmacokinetic Analysis of Piperacillin/ Tazobactam in Korean Patients with Acute Infections
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: For more effective and safer usage of antibiotics, the dosing strategy should be individualized based on the patients’ characteristics, including race. The aim of this study was to investigate the population pharmacokinetic (PK) profiles of piperacillin and tazobactam in Korean patients with acute infections. Materials and Methods: At least four consecutive 2/0.25 g or 4/0.5 g doses of piperacillin/tazobactam (TZP) were intravenously infused over 1 h every 8 h for patients with creatinine clearance (CLcr) ≤50 mL/min or CLcr >50 mL/min, respectively. Blood samples from 33 patients at a steady-state were taken pre-dose and at 0 min, 30 min, and 4-6 h after the fourth infusion. The population PK analysis was conducted using a non-linear mixed-effects method. A likelihood ratio test was used to select significant covariates, with significance levels of P <0.05 for selection and P <0.01 for elimination. Results: Both piperacillin PK and tazobactam PK were well described by a two-compartment model with first-order elimination. Creatinine clearance and body weight, as covariates on clearance (CL) and volume of central compartment (V1), were selected among the covariates possibly affecting PK parameters of both drugs. CL was defined as CL = 2.9 + 4.03 × CLcr /47 for piperacillin and CL = 1.76 + 4.81 × CLcr /47 for tazobactam. V1 was defined as V1 = 19.5 × weight/60 for piperacillin and V1 = 22.6 × weight/60 for tazobactam. Conclusion: The PK profiles of TZP at a steady-state in Korean patients with acute infections were well described by a two-compartment model with first-order elimination. Both piperacillin and tazobactam clearances were significantly influenced by creatinine clearance.
Abstract
Background: For more effective and safer usage of antibiotics, the dosing strategy should be individualized based on the patients’ characteristics, including race. The aim of this study was to investigate the population pharmacokinetic (PK) profiles of piperacillin and tazobactam in Korean patients with acute infections. Materials and Methods: At least four consecutive 2/0.25 g or 4/0.5 g doses of piperacillin/tazobactam (TZP) were intravenously infused over 1 h every 8 h for patients with creatinine clearance (CLcr) ≤50 mL/min or CLcr >50 mL/min, respectively. Blood samples from 33 patients at a steady-state were taken pre-dose and at 0 min, 30 min, and 4-6 h after the fourth infusion. The population PK analysis was conducted using a non-linear mixed-effects method. A likelihood ratio test was used to select significant covariates, with significance levels of P <0.05 for selection and P <0.01 for elimination. Results: Both piperacillin PK and tazobactam PK were well described by a two-compartment model with first-order elimination. Creatinine clearance and body weight, as covariates on clearance (CL) and volume of central compartment (V1), were selected among the covariates possibly affecting PK parameters of both drugs. CL was defined as CL = 2.9 + 4.03 × CLcr /47 for piperacillin and CL = 1.76 + 4.81 × CLcr /47 for tazobactam. V1 was defined as V1 = 19.5 × weight/60 for piperacillin and V1 = 22.6 × weight/60 for tazobactam. Conclusion: The PK profiles of TZP at a steady-state in Korean patients with acute infections were well described by a two-compartment model with first-order elimination. Both piperacillin and tazobactam clearances were significantly influenced by creatinine clearance.
참고문헌 (25)
- Gin A, "Piperacilin-tazobactam: a beta-lactam", beta-lactamase inhibitor combination, 2007, pp.5, 365~383
- Maltezou HC, "Piperacillin", tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery, 2001, pp.20, 643~646
- Tumbarello M, "Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment", Antimicrob Agents Chemother, 51, pp.1987~1994 (2007)
- Peralta G, "Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp bacteremia. A multicentric cohort study", BMC Infect Dis, 12, pp.245~ (2012)
- Turnidge JD, "The pharmacodynamics of β-lactams", Clin Infect Dis, 27, pp.10~22 (1998)
- Mckinnon PS, "Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections", Int J Antimicrob Agents, 31, pp.345~351 (2008)
- Lodise TP, "Application of antimicrobial pharmacodynamics concepts into clinical practice: focus on β-lactam antibiotics: insights form the Society of Infectious Diseases Pharmacists", Pharmacotherapy, 26, pp.1320~1332 (2006)
- Patel N, "Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing refimens in hospitalized patients", Antimicrob Agents Chemother, 54, pp.460~465 (2010)
- Dulhunty JM, "Continous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial", Clin Infect Dis, 56, pp.236~244 (2013)
- Roberts JA, "Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept", Int J Antimicrob Agents, 36, pp.332~339 (2010)
- Johnson JA, "Influence of race or ethnicity on pharmacokinetics of drugs", J Pharm Sci, 86, pp.1328~1333 (1997)
- Chen ML, "Ethnic or racial differences revisited: impact of dosage regimen form on pharmacokinetics and pharmacodynamics", Clin Pharmacokinet, 45, pp.957~964 (2006)
- Jeon S, "Population pharmacokinetic analysis of piperacillin in burn patients", Antimicrob Agents Chemother, 58, pp.3744~3751 (2014)
- Oh KH, "Pharmacokinetics of intravenous piperacillin administration in patients undergoing on-line hemodiafiltration", Antimicrob Agents Chemother, 53, pp.3266~3268 (2009)
- Kiem S, "Population pharmacokinetics of levofloxacin in Korean patients", J Chemother, 28, pp.308~313 (2016)
- Li C, "Population pharmacokinetics and pharmacodynamics of piperacillin", tazobactam in patients with complicated intra-abdominal infection, 2005, pp.56, 388~395
- Felton TW, "Indivisualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy", Anmicrob Agents Chemother, 58, pp.4094~4102 (2014)
- Hayashi Y, "Pharmacokinetic evaluation of piperacillin-tazobactam", Expert Opin Drug Metab Toxicol, 6, pp.1017~1031 (2010)
- Cheymol G, "Effects of obesity on pharmacokinetics implications for drug therapy", Clin Pharmacokinet, 39, pp.215~231 (2000)
- Morgan DJ, "Lean body mass as a predictor of drug dosage. Implications for drug therapy", Clin Pharmacokinet, 26, pp.292~307 (1994)
- Cheatham SC, "Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients", Int J Antimicrob Agents, 41, pp.52~56 (2013)
- Chung EK, "Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients", J Clin Pharmacol, 55, pp.899~908 (2015)
- Tamma PD, "Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia?", Clin Infect Dis, 55, pp.799~806 (2012)
- Karino F, "Nephrotoxicity induced by piperacillin-tazobactam in late elderly Japanese patients with nursing and healthcare associated pneumonia", Biol Pharm Bull, 37, pp.1971~1976 (2014)
- Huang WT, "Neurotoxicity associated with standard doses of piperacillin in an elderly patient with renal failure", Infection, 37, pp.374~376 (2009)